Acumen Pharmaceuticals to report Q1 2026 financial results on May 12 with a live webcast.

Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company focused on Alzheimer's disease treatments, announced it will release its first quarter 2026 financial results on May 12, 2026. The company will host a live conference call and webcast at 8:00 a.m. ET to provide updates on its business and financial status. Acumen is advancing its lead drug candidate, sabirnetug (ACU193), in a Phase 2 clinical trial for early symptomatic Alzheimer's disease, with positive Phase 1 results previously reported. Investors and interested parties can register to participate in the webcast, which will also be archived on the company's website.